Simranjit Singh is the CEO of Guardant Health AMEA (GH AMEA), a joint venture between Guardant Health, Inc. and SoftBank. He has more than 15 years of senior management experience in Asia Pacific working with biopharma, diagnostics and medical device companies. He leads GH AMEA which is a global leader in precision oncology. GH AMEA’s comprehensive genomic profiling (liquid biopsy) tests are available in over 30 different markets across Asia, Middle East and Africa and it has two regional offices in Singapore and Tokyo.

Prior to Guardant Health, Simranjit was the Vice President of the Medical Devices and Diagnostics Division at IQVIA where he delivered exponential revenue growth by driving business transformation and growing the clinical research, consulting and regulatory business to advance market share in Asia Pacific.  Simran holds a BSc in Biomedical Sciences from the National University of Singapore and an MBA from the University of Chicago.